Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medco and Caremark agree to transparency

Executive Summary

Seven new PBMs have agreed to adhere to transparency standards set by the HR Policy Association. Medco, Caremark, Blue Cross & Blue Shield of Alabama, Catalyst, Cigna, HealthTrans, and Restat have been certified according to HR Policy's Transparency in Pharmaceutical Purchasing Solutions principles, the coalition of large employers announced July 24. Aetna, MedImpact and Walgreens were recertified (1"The Pink Sheet" Aug. 15, 2005, p. 15). The TIPPS principles were updated to include new requirements related to specialty pharmacy. Express Scripts is not participating in the HR Policy Association program...

You may also be interested in...



PBM Transparency: Three Firms Agree To Standards Set By Employer Group

Three pharmacy benefit management companies are in the vanguard of firms that have committed to giving up profits based on drug price differentials and rebates

New EU Filings

Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

P&G Restores Volume Growth In Beauty, Grooming After Pricing Run

Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS047433

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel